Novel genes associated with lymph node metastasis in triple negative breast cancer

Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype with the worst prognosis and no targeted treatments. TNBC patients are more likely to develop metastases and relapse than patients with other breast cancer subtypes. We aimed to identify TNBC-specific genes and genes associated with lymph node metastasis, one of the first signs of metastatic spread. A total of 33 TNBCs were used; 17 of which had matched normal adjacent tissues available, and 15 with matched lymph node metastases. Gene expression microarray analysis was used to reveal genes that were differentially expressed between these groups. We identified and validated 66 genes that are significantly altered when comparing tumours to normal adjacent samples. Further, we identified 83 genes that are associated with lymph node metastasis and correlated these with miRNA-expression. Pathway analysis revealed their involvement in DNA repair, recombination and cell death, chromosomal instability and other known cancer-related pathways. Finally, four genes were identified that were specific for TNBC, of which one was associated with overall survival. This study has identified novel genes involved in LN metastases in TNBC and genes that are TNBC specific that may be used as treatment targets or prognostic indicators in the future.

[1]  E. Rassart,et al.  Apolipoprotein D Inhibits Platelet-Derived Growth Factor-BB–Induced Vascular Smooth Muscle Cell Proliferated by Preventing Translocation of Phosphorylated Extracellular Signal Regulated Kinase 1/2 to the Nucleus , 2003, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Natasha J. Caplen,et al.  Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA , 2011, Breast Cancer Research and Treatment.

[3]  J. Mattick,et al.  Non-coding RNA. , 2006, Human molecular genetics.

[4]  Christophe Lemetre,et al.  MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer , 2009, Breast Cancer Research.

[5]  J. Baak,et al.  Co-expression of estrogen receptor α and Apolipoprotein D in node positive operable breast cancer – possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients , 2009, Acta oncologica.

[6]  Jean-Marc Guinebretière,et al.  A six-gene signature predicting breast cancer lung metastasis. , 2008, Cancer research.

[7]  Li Ma,et al.  MicroRNA control of epithelial–mesenchymal transition and metastasis , 2012, Cancer and Metastasis Reviews.

[8]  M. Duffy,et al.  Targeted therapy for triple‐negative breast cancer: Where are we? , 2012, International journal of cancer.

[9]  R. Lidereau,et al.  Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers , 2011, EMBO molecular medicine.

[10]  L. Godsel,et al.  Discriminating roles of desmosomal cadherins: beyond desmosomal adhesion. , 2007, Journal of dermatological science.

[11]  T. Sørlie,et al.  Triple‐negative breast cancer: Present challenges and new perspectives , 2010, Molecular oncology.

[12]  R. Scott,et al.  The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. , 2014, Carcinogenesis.

[13]  L. Carey,et al.  Triple-negative breast cancer: disease entity or title of convenience? , 2010, Nature Reviews Clinical Oncology.

[14]  A. Haholu,et al.  miR-205 and miR-200c: Predictive Micro RNAs for Lymph Node Metastasis in Triple Negative Breast Cancer , 2014, Journal of breast cancer.

[15]  Rui Xia,et al.  Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer , 2014, Tumor Biology.

[16]  S. Lakhani,et al.  Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer , 2014, Oncogenesis.

[17]  John Quackenbush,et al.  Confounding effects in "A six-gene signature predicting breast cancer lung metastasis". , 2009, Cancer research.

[18]  A. Mackiewicz,et al.  Expression of interleukin‐6, interleukin‐6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma , 2000, Cancer.

[19]  Parantu K. Shah,et al.  Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression , 2008, Molecular systems biology.

[20]  C. Croce,et al.  Oncosuppressive role of p53‐induced miR‐205 in triple negative breast cancer , 2012, Molecular oncology.

[21]  V. Adamo,et al.  Prognostic markers in triple-negative breast cancer (TNBC): The role of androgen receptor, e-cadherin, and Ki67. , 2015 .

[22]  C. R. Leemans,et al.  Using tissue adjacent to carcinoma as a normal control: an obvious but questionable practice , 2004, The Journal of pathology.

[23]  C. Croce,et al.  MicroRNA signatures in human cancers , 2006, Nature Reviews Cancer.

[24]  Soo Young Lee,et al.  microRNA-101 inhibits lung cancer invasion through the regulation of enhancer of zeste homolog 2. , 2011, Experimental and therapeutic medicine.

[25]  D. Jäger,et al.  Identification of a tissue-specific putative transcription factor in breast tissue by serological screening of a breast cancer library. , 2001, Cancer research.

[26]  Carme Camps,et al.  microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. , 2011, Cancer research.

[27]  Brian J. Wilson,et al.  Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway , 2008, Molecular Cancer.

[28]  S. Narod,et al.  Pattern of metastatic spread in triple-negative breast cancer , 2009, Breast Cancer Research and Treatment.

[29]  Shenming Wang,et al.  MicroRNA Profiling Implies New Markers of Chemoresistance of Triple-Negative Breast Cancer , 2014, PloS one.

[30]  J. Avery Critical review. , 2006, The Journal of the Arkansas Medical Society.

[31]  P. Billon,et al.  Precise deposition of histone H2A.Z in chromatin for genome expression and maintenance. , 2012, Biochimica et biophysica acta.

[32]  Yiran Huang,et al.  Downregulated MEG3 activates autophagy and increases cell proliferation in bladder cancer. , 2013, Molecular bioSystems.

[33]  R. Weinberg,et al.  A Perspective on Cancer Cell Metastasis , 2011, Science.

[34]  Volker Hovestadt,et al.  Molecular and Cellular Pathobiology MicroRNA Sequence and Expression Analysis in Breast Tumors by Deep Sequencing , 2011 .

[35]  Matthew J. Ellis,et al.  Molecular Basis of Triple Negative Breast Cancer and Implications for Therapy , 2011, International journal of breast cancer.

[36]  Howard Y. Chang,et al.  Long noncoding RNA HOTAIR reprograms chromatin state to promote cancer metastasis , 2010, Nature.

[37]  S. Henikoff,et al.  Changes in H2A.Z occupancy and DNA methylation during B-cell lymphomagenesis. , 2010, Genome research.

[38]  Sun-Mi Park,et al.  The role of let-7 in cell differentiation and cancer. , 2010, Endocrine-related cancer.

[39]  E. Winer,et al.  Poly(ADP-Ribose) Polymerase Inhibition: “Targeted” Therapy for Triple-Negative Breast Cancer , 2010, Clinical Cancer Research.

[40]  A. Chinnaiyan,et al.  The emergence of lncRNAs in cancer biology. , 2011, Cancer discovery.

[41]  F. Slack,et al.  let-7 microRNAs in development, stem cells and cancer. , 2008, Trends in molecular medicine.

[42]  Fei Chen,et al.  Microprocessor of microRNAs: regulation and potential for therapeutic intervention , 2010, Molecular Cancer.

[43]  G. Botti,et al.  Triple negative breast cancer: from molecular portrait to therapeutic intervention. , 2010, Critical reviews in eukaryotic gene expression.

[44]  S. Vacher,et al.  Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.

[45]  Asli Silahtaroglu,et al.  Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. , 2007, Cancer research.

[46]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[47]  Chien-Feng Li,et al.  TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma , 2013, Tumor Biology.

[48]  A. Nissan,et al.  Multimarker RT–PCR assay for the detection of minimal residual disease in sentinel lymph nodes of breast cancer patients , 2006, British Journal of Cancer.

[49]  A. Levine,et al.  Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer , 2012, Proceedings of the National Academy of Sciences.

[50]  Pengjun Wang,et al.  Overexpression of the long non‐coding RNA MEG3 impairs in vitro glioma cell proliferation , 2012, Journal of cellular biochemistry.

[51]  G. Mills,et al.  Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. , 2013, Cancer research.

[52]  A. Tutt,et al.  Triple negative tumours: a critical review , 2007, Histopathology.

[53]  D. Jäger,et al.  The differentiation antigen NY‐BR‐1 is a potential target for antibody‐based therapies in breast cancer , 2007, International journal of cancer.

[54]  R. Chacón,et al.  REVIEW Triple-negative , 2022 .

[55]  Z. Szallasi,et al.  The CIN4 Chromosomal Instability qPCR Classifier Defines Tumor Aneuploidy and Stratifies Outcome in Grade 2 Breast Cancer , 2013, PloS one.

[56]  J. A. Garrote-Adrados,et al.  Expression and potential role of apolipoprotein D on the death–survival balance of human colorectal cancer cells under oxidative stress conditions , 2013, International Journal of Colorectal Disease.

[57]  S. Hilsenbeck,et al.  Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency , 2013, Breast Cancer Research.

[58]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[59]  J. Forbes,et al.  Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer , 2014, BMC Cancer.

[60]  C. Croce,et al.  Breast cancer signatures for invasiveness and prognosis defined by deep sequencing of microRNA , 2012, Proceedings of the National Academy of Sciences.

[61]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[62]  C. Croce,et al.  Integrated MicroRNA and mRNA Signatures Associated with Survival in Triple Negative Breast Cancer , 2013, PloS one.

[63]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[64]  S. Narod,et al.  Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence , 2007, Clinical Cancer Research.

[65]  E. Rassart,et al.  Modulation of apolipoprotein D expression and translocation under specific stress conditions. , 2007, Biochimica et biophysica acta.

[66]  C. Benz,et al.  Coordinate Suppression of ERBB2 and ERBB3 by Enforced Expression of Micro-RNA miR-125a or miR-125b* , 2007, Journal of Biological Chemistry.

[67]  King-Jen Chang,et al.  Molecular Characteristics and Metastasis Predictor Genes of Triple-Negative Breast Cancer: A Clinical Study of Triple-Negative Breast Carcinomas , 2012, PloS one.

[68]  V. Castranova,et al.  Reviewof microRNAs: regulation and potential for therapeutic intervention , 2010 .

[69]  Hailong Wu,et al.  MicroRNA-101-mediated Akt activation and estrogen-independent growth , 2011, Oncogene.

[70]  D. Jäger,et al.  Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases , 2006, Clinical Cancer Research.

[71]  J. Baak,et al.  Biologic profiling of lymph node negative breast cancers by means of microRNA expression , 2010, Modern Pathology.

[72]  M. West,et al.  Gene expression predictors of breast cancer outcomes , 2003, The Lancet.

[73]  R. Qin,et al.  Long non-coding RNA MEG3 inhibits the proliferation of cervical carcinoma cells through the induction of cell cycle arrest and apoptosis. , 2013, Neoplasma.

[74]  T. Mak,et al.  ANP32E is a histone chaperone that removes H2A.Z from chromatin , 2014, Nature.

[75]  Z. Szallasi,et al.  A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers , 2006, Nature Genetics.

[76]  M. Čížková,et al.  Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. , 2009, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[77]  L. Holmberg,et al.  Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control , 2013, BMC Genomics.

[78]  L. Esserman,et al.  A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer , 2010, Breast Cancer Research.